New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - nedocromil sodium 1.4085%{relative} (2 mg/dose);   - aerosol inhaler, metered dose - 2 mg/dose - active: nedocromil sodium 1.4085%{relative} (2 mg/dose)   excipient: apaflurane macrogol 600 menthol povidone - tilade cfc-free is indicated in the treatment of bronchial asthma (whether extrinsic or intrinsic in nature, and including asthmatic bronchitis, late onset asthma, exercise induced asthma, and bronchospasm provoked by a variety of stimuli such as cold air, inhaled allergens, atmospheric pollutants and other irritants). tilade cfc-free is intended for regular prophylactic treatment and not for symptomatic relief. in the management of asthma, tilade cfc-free improves pulmonary function, reduces the frequency and severity of attacks and reduces bronchospasm, cough and bronchial hyper-responsiveness. in patients already receiving treatment for their asthma, tilade cfc-free can be given in addition to all existing therapies and will in many cases provide added therapeutic benefit. having established this benefit of tilade cfc-free, it may be possible to gradually reduce or eliminate concomitant therapy.

United States - English - NLM (National Library of Medicine)

akorn - nedocromil sodium (unii: et8if4ks1t) (nedocromil - unii:0b535e0bn0) - nedocromil sodium 20 mg in 1 ml - nedocromil sodium ophthalmic solution is indicated for the treatment of itching associated with allergic conjunctivitis. nedocromil sodium ophthalmic solution is contraindicated in those patients who have shown hypersensitivity to nedocromil sodium or to any of the other ingredients.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - nedocromil sodium - eye drops - 20mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - nedocromil sodium - eye drops - 20mg/1ml

Canada - English - Health Canada

sanofi-aventis canada inc - cromolyn sodium - metered-dose aerosol - 1mg - cromolyn sodium 1mg - mast-cell stabilizers

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - nedocromil sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - budesonide, quantity: 80 microgram; formoterol fumarate dihydrate, quantity: 2.25 microgram - inhalation, pressurised - excipient ingredients: apaflurane; macrogol 1000; povidone - asthma symbicort rapihaler is indicated in adults and adolescents (12 years and older), for the treatment of asthma to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see section 4.2 dose and method of administration). chronic obstructive pulmonary disease (copd) symbicort 200/6 is indicated for the symptomatic treatment of moderate to severe copd (fev1 < or = 50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or a history of recurrent exacerbations. symbicort is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - formoterol fumarate dihydrate, quantity: 2.25 microgram; budesonide, quantity: 40 microgram - inhalation, pressurised - excipient ingredients: apaflurane; macrogol 1000; povidone - asthma symbicort rapihaler is indicated in adults and adolescents (12 years and older), for the treatment of asthma to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see section 4.2 dose and method of administration). chronic obstructive pulmonary disease (copd) symbicort 200/6 is indicated for the symptomatic treatment of moderate to severe copd (fev1 < or = 50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or a history of recurrent exacerbations. symbicort is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - budesonide, quantity: 160 microgram; formoterol fumarate dihydrate, quantity: 4.5 microgram - inhalation, pressurised - excipient ingredients: povidone; macrogol 1000; apaflurane - asthma symbicort rapihaler is indicated in adults and adolescents (12 years and older), for the treatment of asthma to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see section 4.2 dose and method of administration). chronic obstructive pulmonary disease (copd) symbicort 200/6 is indicated for the symptomatic treatment of moderate to severe copd (fev1 < or = 50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or a history of recurrent exacerbations. symbicort is not indicated for the initiation of bronchodilator therapy in copd.

United States - English - NLM (National Library of Medicine)

allergan, inc. - nedocromil sodium (unii: et8if4ks1t) (nedocromil - unii:0b535e0bn0) - alocril ® ophthalmic solution is indicated for the treatment of itching associated with allergic conjunctivitis. alocril ® ophthalmic solution is contraindicated in those patients who have shown hypersensitivity to nedocromil sodium or to any of the other ingredients.